Entia Biosciences, Inc.

Equities

ERGO

US29384E1047

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:08:36 2024-04-26 am EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2017	Entia Biosciences, Inc. Announces Management Changes	CI
2017	Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt	CI

Entia Biosciences, Inc announced that it has received $0.495 million in funding

May 25, 2015

On May 26, 2015, Entia Biosciences, Inc (OTCPK:ERGO) closed the transaction. The company has received $290,000 in its second and final tranche and received a total of $495,000 from 11 investors in the transaction. The company expected to receive $550,000 in the transaction.

Latest news about Entia Biosciences, Inc.

Entia Biosciences, Inc. Announces Management Changes	17-12-04	CI
Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt	17-05-18	CI
Entia Biosciences Enters Exclusive Worldwide Licensing Agreement with GROH BEAUTY CORP for its Groh Beauty Products Line	17-02-24	CI
Patrick Neville acquired worldwide rights to GROH beauty care product line from Entia Biosciences, Inc.	17-02-23	CI
Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt	16-04-13	CI
Entia Biosciences, Inc announced that it has received $0.05 million in funding	15-12-06	CI
Entia Biosciences, Inc. Announces Resignation of Philip A. Sobol from the Board of Directors	15-12-04	CI
Entia Biosciences, Inc announced that it expects to receive $1 million in funding.	15-11-24	CI
Entia Biosciences, Inc. Announces Executive Changes	15-10-08	CI
Entia Biosciences, Inc. Announces Termination of Devin Andres as Chief Operating Officer	15-09-08	CI
Entia Biosciences, Inc announced that it has received $0.48 million in funding.	15-07-28	CI
Entia Biosciences, Inc announced that it has received $0.495 million in funding	15-05-25	CI
Entia Biosciences, Inc announced that it expects to receive $0.4 million in funding.	15-04-22	CI
Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt	15-03-29	CI
Entia Biosciences, Inc cancelled the acquisition of Funguys, LLC.	14-12-16	CI
Entia Biosciences, Inc. Announces Partnership Agreement with Tan Republic Franchise Company	14-05-14	CI
Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt	14-03-31	CI
Entia Biosciences, Inc entered into an asset purchase agreement to acquire Funguys, LLC for $0.21 million.	13-12-18	CI
Entia Biosciences, Inc. announced that it has received $1.5 million in funding	13-11-12	CI
Entia Biosciences, Inc announced that it has received $0.05 million in funding.	13-08-13	CI
Entia Biosciences, Inc announced that it has received $0.04 million in funding.	13-06-11	CI
Entia Biosciences, Inc Appoints Sabrina Jetton as Director of Marketing	13-05-15	CI
Entia Biosciences, Inc Auditor Raises 'Going Concern' Doubt	13-04-01	CI
Entia Biosciences, Inc. Appoints Devin Andres as Chief Operating Officer	13-03-19	CI
Entia Biosciences, Inc Begins Multi-site Clinical Trial of Medical Food for Treatment of Diabetes and Anemia	12-06-06	CI

Chart Entia Biosciences, Inc.

Duration

Period

More charts

Company Profile

Entia Biosciences, Inc. develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Company also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The Company's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The Company's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENTIA BIOSCIENCES, INC.	-.--%	3.41K
MODERNA, INC.	+26.28%	42.68B
IQVIA HOLDINGS INC.	-3.99%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B
BIO-TECHNE CORPORATION	-2.02%	11.55B

Other Biotechnology & Medical Research